Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Methoxy polyethylene glycol-epoetin beta
Drug ID BADD_D01421
Description Methoxy polyethylene glycol-epoetin beta is a chemically synthesised Erythropoiesis Stimulating Agent (ESA) with a longer half-life than erythropoietin. ESA is used to increase synthesis of red blood cells to treat chronic kidney disease associated anemia.
Indications and Usage For the treatment of patients with anaemia associated with chronic kidney disease. Not a substitute for RBC transfusion if immediate correction of anemia is required.
Marketing Status approved
ATC Code B03XA03
DrugBank ID DB09107
KEGG ID D09998
MeSH ID C508420
PubChem ID Not Available
TTD Drug ID D0K3XP
NDC Product Code 59353-407; 59353-408; 59353-401; 59353-405; 59353-403; 59353-404; 59353-400; 59353-402; 59353-406
UNII LR3UXN0193
Synonyms continuous erythropoietin receptor activator | CERA (erythropoietin receptor activator) | methoxy polyethylene glycol-epoetin beta | epoetin beta pegol | Mircera
Chemical Information
Molecular Formula Not Available
CAS Registry Number 677324-53-7
SMILES Not Available
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Aplasia pure red cell01.03.03.001; 10.02.01.003---
Arteriovenous fistula thrombosis12.02.01.006; 24.01.01.017---
Back pain15.03.04.005--
Constipation07.02.02.001--
Cough22.02.03.001--
Diarrhoea07.02.01.001--
Headache17.14.01.001--
Hypersensitivity10.01.03.003--
Hypertension24.08.02.001--
Hypervolaemia02.05.04.019; 14.05.06.003---
Hypotension24.06.03.002--
Muscle spasms15.05.03.004--
Nasopharyngitis11.01.13.002; 22.07.03.002---
Pain in extremity15.03.04.010--
Stevens-Johnson syndrome10.01.01.045; 11.07.01.005; 12.03.01.014; 23.03.01.007--
Toxic epidermal necrolysis10.01.01.006; 11.07.01.006; 12.03.01.015; 23.03.01.008--
Upper respiratory tract infection11.01.13.009; 22.07.03.011--
Urinary tract infection11.01.14.004; 20.08.02.001--
Vomiting07.01.07.003--
Arteriovenous fistula site complication12.02.01.008; 24.03.02.018---
Procedural hypotension12.02.05.026; 24.06.03.010---
The 1th Page    1    Total 1 Pages